

Client: ACCESS MEDICAL LABS, 0 1 Patient: TEST, PATIENT

5151 CORPORATE WAY Phone: DOB. 01/01/1980 Age:44 Sex: F ( ) -JUPITER, FL 33458

Address 1: Address 2:

Fasting: N

(561) 745-1233 City: Phys: SARA, ALAN State: Zip: Page:1

Acc# 005261164 Coll. Date: 11/20/24 Recv. Date: 11/20/24 Print Date: 11/20/24 Chart# Coll. Time: 00:00 AM Recv. Time:07:31 AM Print Time: 15:39 11/20/24 14:37 Final report date: 11/20/24 First reported on:

Report Status: FINAL

Test Name	Results	Reference Range	Units
COMPLETE BLOOD COUNT			
WHITE BLOOD CELL	10.0	3.9 - 11.4	K/ul
RED BLOOD CELL	3.50 L	3.80 - 5.50	M/ul
HEMOGLOBIN	15	11.5 - 15.2	g/dl
HEMATOCRIT	45	37.0 - 48.0	%
MCV	85	83 - 102	fl
MCH	29.5	26.0 - 34.0	pg
MCHC	31.0	29.5 - 35.5	g/dl
RDW	10.0 L	11.0 - 15.5	%
PLATELET COUNT	350	140 - 400	k/ul
MPV	9.0	7.5 - 11.6	fl
AUTOMATED DIFFERENTIAL  Monocyte %	10	2.0 - 13.0	%
•	10	2.0 13.0	70
MANUAL DIFFERENTIAL			
Lymphocyte %	35	Not Estab.	%
HEMATOLOGY TESTS			
Sedimentation Rate	2	0 - 30	mm/hr
GENERAL CHEMISTRY			
GLUCOSE	95	65 - 100	mg/dl
BUN	10	6 - 20	mg/dl
CREATININE, SERUM	1.0	0.5 - 1.0	mg/dl
URIC ACID	5.0	3.1 - 7.8	mg/dl
SODIUM	140	136 - 145	mmol/L
POTASSIUM	5.0	3.5 - 5.1	mmol/L
CHLORIDE	106	100 - 110	mmol/L
CO2	26	20 - 31	mmol/L
CALCIUM	9.0	8.3 - 10.6	mg/dl
TOTAL PROTEIN	6.5	5.7 - 8.2	g/dl
ALBUMIN	3.5	3.2 - 4.8	g/dl
GLOBULIN	3.0	2.2 - 3.7	g/dl
BILIRUBIN, TOTAL	1.0	0.3 - 1.2	mg/dl
ALKALINE PHOSPHATASE	45	37 - 98	U/L
(Continued o	on Next Page)		



Client: ACCESS MEDICAL LABS, 0 1 Patient: TEST, PATIENT

5151 CORPORATE WAY

JUPITER, FL 33458

Phone: ( ) - DOB. 01/01/1980 Age:44 Sex: F

Address 1: Fasting: N

Address 1: Address 2:

Phys: SARA, ALAN (561) 745-1233 City: State: Zip: Page:2

 Acc#
 005261164
 Coll. Date: 11/20/24
 Recv. Date: 11/20/24
 Print Date: 11/20/24

 Chart#
 Coll. Time: 00:00 AM
 Recv. Time:07:31 AM
 Print Time: 15:39

 First reported on:
 11/20/24 14:37
 Final report date:
 11/20/24

Report Status: FINAL

Test Name	Results	Reference Range	Units
GENERAL CHEMISTRY (Continued)			
ALT	20	0 - 48	U/L
AST	21	0 - 32	U/L
Albumin/Globulin Ratio	1.2	0.8 - 2.0	
BUN/CREAT RATIO	N/A	7.3 - 21.7	
GFR, estimated	64		ml/min

If African-American, result is: >60

 $\hbox{\tt Calculation of estimated GFR is based on the MDRD Study prediction equation}$ 

\*\*\*\*Five Stages of Chronic Kidney Disease\*\*\*\*

*Stage*	*GFR Level*	*Description*
Stage 1	90 ml/min or more	Healthy Kidneys or Kidney
		damage with normal or high GFR
Stage 2	60 to 89 ml/min	Kidney damage and mild decrease
		in GFR
Stage 3	30 to 59 ml/min	Moderate decrease in GFR
Stage 4	15 to 29 ml/min	Severe decrease in GFR
Stage 5	< 15 ml/min	Kidney failure, or on dialysis

## **CARDIAC EVALUATION**

CK, Total 50 34 - 145 U/L

## **DIABETES EVALUATION**

HEMOGLOBIN A1C 4.5 < 5.7 %

\*\*\*Diagnosis\*\*\*

Normal

Prediabetes

Diabetes

\*\*\*HbA1c Level\*\*\*

< 5.7 %

6.4 %

- or > 6.5 %

Having prediabetes is a Risk Factor for getting type 2 diabetes. Within the prediabetes range(5.7-6.4), the higher the HbAlc,the greater the risk of diabetes. HbAlc target for diabetics depend on their history and health.

## **IRON/ANEMIA EVALUATION**

IRON	50	50 - 170	ug/dl
TOTAL IRON-BIND. CAPACITY	300	250 - 425	ug/dl
% IRON SATURATION	17	15 - 50	%
FERRITIN	20	7.3 - 270.7	ng/ml
VITAMIN B12	500	211 - 911	pg/ml

(Continued on Next Page)



Client: ACCESS MEDICAL LABS, 0 1 Patient: TEST, PATIENT

5151 CORPORATE WAY

JUPITER, FL 33458

Phone: ( ) - DOB. 01/01/1980 Age:44 Sex: F

Address 1: Fasting: N

Address 2:

Phys: SARA, ALAN (561) 745-1233 City: State: Zip: Page:3

 Acc#
 005261164
 Coll. Date: 11/20/24
 Recv. Date: 11/20/24
 Print Date: 11/20/24

 Chart#
 Coll. Time: 00:00 AM
 Recv. Time:07:31 AM
 Print Time: 15:39

First reported on: 11/20/24 14:37 Final report date: 11/20/24

Report Status: FINAL

Report Status: FINAL				
Test Name	Results	Reference Range	Units	
IRON/ANEMIA EVALUATION (Continued)				
FOLATE, SERUM	20	5.38 - 24.0	ng/ml	
CORONARY RISK				
TRIGLYCERIDES	100	.1.5.0		
CHOLESTEROL, TOTAL	180		mg/dl	
HDL CHOLESTEROL	35		mg/dl	
			mg/dl	
LDL CHOLESTEROL, calc	127	<b>H</b> <100	mg/dl	
CHOL/HDL RATIO	5.1	<b>H</b> <4.4		
	The higher the Ratio, the higher CHD risk.			
CRP, Cardio	2.0	<3	mg/L	
	**Risk of Cardiovasular Disease**			
Low R	isk	CRP < 1.0 mg/L		
Mediu	m Risk	CRP 1.0 - 3.0 mg/L		
High	Risk	CRP > 3.0 mg/I	_	
HOMOCYSTEINE	10	4.5 - 15.0	umol/L	
	Ideal level <8.0 umol/L			
LIPOPROTEIN (a)	12	<30	mg/dl	
PLAC (Lp-PLA2)	68	< 250	U/L	
	s a specific marker of v			

PLAC (Lp-PLA2) is a specific marker of vascular inflamation associated with atherosclerosis. It is also a marker for Cardiac disease and Stroke. On Oct. 31,2016 we transitioned to the FDA approved Diadexus traced calibration method. As a result of this transition the reference range has been changed to the following: < 250 U/L

This result cannot be compared with previous results, before 10/31/2016.

Vitamin D,25-OH,Total 29 L 30 - 100 ng/ml

Notes:

Therapy is based on the measurement of Total Vitamin D (25-OH).

Most experts agree that Vitamin D deficiency should be = or < 20 ng/ml.

(Continued on Next Page)

Client: ACCESS MEDICAL LABS, 0

5151 CORPORATE WAY

JUPITER, FL 33458

Patient: TEST, PATIENT

Phone: ( ) -

DOB. 01/01/1980

Age:44 Sex: F

Address 1: Address 2:

Phys: SARA, ALAN

(561) 745-1233

City:

State:

Zip:

Page:4

Fasting: N

Acc# 005261164 Chart#

First reported on:

Coll. Date: 11/20/24 Coll. Time: 00:00 AM 11/20/24 14:37 Recv. Date: 11/20/24 Recv. Time:07:31 AM Final report date: Print Date: 11/20/24 Print Time: 15:39

11/20/24

Report Status: FINAL

**Test Name** 

est ivallie

Results

Reference Range

Units

# **CORONARY RISK (Continued)**

Vitamin D insufficiency is recognized as 21 - 29 ng/ml.

The preferred level for Vitamin D (25-OH) is recommended to be 30 - 100

ng/ml.

Vitamin D > 150 ng/ml is considered potentially toxic.

## **THYROID TESTING**

Reverse T3, LC/MS/MS	10	5.0 - 25.0	ng/dL
T3, FREE	2.3	2.3 - 4.2	pg/ml
T4, FREE	1.3	0.89 - 1.76	ng/dl
TSH	1.020	0.550 - 4.780	uIU/ml
THYROID PEROXIDASE Abs	35	<60	IU/ml
THYROGLOBULIN Abs	12.0	<60	IU/ml

## **TUMOR MARKERS**

CEA 2.0 <3.5 ng/ml

The above test is performed by Siemens Atellica IA. Patient results performed by different assay methods may not be comparable.

## **ENDOCRINE EVALUATION**

FSH 12 mIU/ml

\*\*Female Reference Ranges\*\*

Follicular Phase 2.5 - 10.2 mIU/mL Mid Cycle Peak 3.4 - 33.4 mIU/mL Luteal Phase 1.5 - 9.1 mIU/mL Pregnant < 0.3 mIU/mL Post Menopausal 23.0 - 116.3 mIU/mL

LH 5.0 mIU/ml

\*\*Female Reference Ranges\*\*

Follicular Phase 1.9 - 12.5 mIU/mL Mid Cycle Peak 8.7 - 76.3 mIU/mL

(Continued on Next Page)



	MEDICAL LABS-	(800)/20-8380		
Client: ACCESS MEDICAL L 5151 CORPORATE W. JUPITER, FL 33458		Patient: TEST, PATI Phone: ( ) - Address 1: Address 2:	DOB. 01/01/1980	Age:44 Sex: F Fasting: N
Phys: SARA, ALAN	(561) 745-1233		State: Z	ip: Page:5
Acc# 005261164 Chart# First reported on:	Coll. Date: 11/20/24 Coll. Time: 00:00 AM 11/20/24 14:37	Recv. Date: 11/20/24 Recv. Time:07:31 AM Final report date:	Print Date: 11/20/ Print Time: 15:39 11/20/24	24
Report Status: FINAL				
Test Name		Results	Reference Range	Units
ENDOCRINE EVALUA	TION (Continued)			
	Luteal Phase Pregnant Post Menopausal	0.5 - 16.9 mIU/mL <0.1 - 1.5 mIU/mL 5.0 - 55.2 mIU/mL		
PROGESTERONE		35		ng/mL
	**Female Refer	rence Ranges**		
	Luteal phase 3 Mid-luteal phase 4	0.00 - 1.40 ng/mL 3.34 - 25.56 ng/mL 4.44 - 28.03 ng/mL 0.00 - 0.73 ng/mL		
	**Pregna	ant**		
	Second trimester 2	11.22 - 90.00 ng/mL 25.55 - 89.40 ng/mL 48.40 - 422.5 ng/mL		
PREGNENOLONE, LC/	MS/MS	23	2.5 - 75.0	ng/dL
	Effective 3/13/17, Pre	egnenolone is perform	ed in-house on LC/M	IS/MS.
ESTRADIOL, LC/MS		400	<440	pg/mL
	Premenopausal - Follic Premenopausal - Luteal Postmenopausal		pg/mL	
DHEA-SULFATE DIHYDROTESTOSTER	ONE LC/MS	<b>25 L</b> 15	25.9 - 460.2 <30.0	ug/dl ng/dL
TESTOSTERONE, TOT.	AL LC/MS	45	7.0 - 55.0	ng/dL
	Premenopausal 10.0 - Postmenopausal 7.0 -	- 55.0 ng/dL - 40.0 ng/dL		
SEX HORMONE BIND	GLOBULIN (Continued on Next Pa	65 age)		nmol/L



Client: ACCESS MEDICAL LABS, 0 1 Patient: TEST, PATIENT

5151 CORPORATE WAY

JUPITER, FL 33458

Phone: ( ) - DOB. 01/01/1980 Age:44 Sex: F

Address 1: Fasting: N

Address 2:

Phys: SARA, ALAN (561) 745-1233 City: State: Zip: Page:6

 Acc#
 005261164
 Coll. Date: 11/20/24
 Recv. Date: 11/20/24
 Print Date: 11/20/24

 Chart#
 Coll. Time: 00:00 AM
 Recv. Time:07:31 AM
 Print Time: 15:39

First reported on: 11/20/24 14:37 Final report date: 11/20/24

Report Status: FINAL

Test Name Results Reference Range Units

## **ENDOCRINE EVALUATION (Continued)**

\*\*Female Reference Ranges\*\*

Premenopausal 11 - >180.00 nmol/L Postmenopausal 23 - 159 nmol/L

IGF-1 120 113 - 172 ng/mL

Access Medical Laboratories uses Siemens Healthcare Diagnostics as the supplier for IGF-1 Immunoassay Testing System. Siemens Introduced a Restandardization of IGF-1 assay using WHO 1st International Standard (IS), NIBSC Code 02/254.

(15),N1B5C Code 02/254.

CORTISOL 20 ug/dl

\*\*Normal individuals\*\*

Morning am 7-9: 5.2 - 22.5 ug/dL Afternoon pm 3-5: 3.4 - 16.8 ug/dL

Testosterone, Free LC/MS Lab Developed Testing 0.5 0.2 - 2.6 ng/dl

Serum Pregnenolone, DHT, Estrone, Estriol, RT3, CO-Q10, Total Testosterone LC/MS, Androstenedione LC/MS, Progesterone LC/MS, and Estradiol LC/MS were developed and their performance characteristics determined by Access Medical Laboratories.

It has not been cleared or approved by the FDA.

The laboratory is regulated under CLIA and qualified to perform high-complexity testing. These tests are used for clinical purposes.

It should not be regarded as investigational or for research.

(Continued on Next Page)

Client: ACCESS MEDICAL LABS, 0 1 TEST, PATIENT Patient: 5151 CORPORATE WAY Phone: ( ) -DOB. 01/01/1980 Age:44 Sex: F JUPITER, FL 33458 Address 1: Fasting: N Address 2: Phys: SARA, ALAN (561) 745-1233 City: State: Zip: Page:7 Acc# 005261164 Coll. Date: 11/20/24 Recv. Date: 11/20/24 Print Date: 11/20/24 Chart# Coll. Time: 00:00 AM Recv. Time:07:31 AM Print Time: 15:39 First reported on: 11/20/24 14:37 Final report date: 11/20/24 Report Status: FINAL **Test Name** Results Units Reference Range **AUTO IMMUNE. Antinuclear Antibodies, MFI** ANA Screen NEGATIVE NEGATIVE ANA INTERPRETATION GUIDE \*\*\*\*\* CLINICAL SUSPICION ANTI NUCLEAR AUTO ANTIBODIES INVOLVED \_\_\_\_\_ \_\_\_\_\_ SLE ANTI-dsDNA, ANTI-Sm, ANTI-RIBOSOMAL P, ANTI-CHROMATIN, ANTI-SSA (one or more positive) SCLERODERMA ANTI-SCL-70, ANTI-CENTROMERE (one or both positive) SJOGREN'S SYNDROME ANTI-SS-A, ANTI-SS-B (both positive) ANTI-JO-1 POLYMYOSITIS OR DERMATOMYOSITIS DRUG-INDUCED LUPUS ANTI-CHROMATIN (no further testing) ANTI-SM/RNP, ANTI-RNP, ANTI-CHROMATIN MIXED CONNECTIVE TISSUE DISEASE(MCTD) (at least RNP positive) **METALS EVALUATION** Magnesium, Packed RBC 5.0 4.20 - 6.80 mg/dL Zinc, Packed RBC 800 794.0 - 1470 ug/dL Lab Developed Test All Metal Testing on ICP-MS/MS were developed and their performance characteristic determined by Access Medicals Labs. They have not been cleared or approved by the FDA. The laboratory is regulated under CLIA and qualified to perform high complexity testing. These tests are used for clinical purposes. They should not be regarded as investigational or for research. \*\*\*\*\* \*1 **IODINE** 20 COMMENTS: END OF REPORT (Continued on Next Page)



Client: ACCESS MEDICAL LABS, 0

5151 CORPORATE WAY

JUPITER, FL 33458

Patient: TEST, PATIENT

Director: Alan Sara, M.D

Phone: ( ) -

DOB. 01/01/1980

Age:44 Sex: F

Fasting: N

Address 1: Address 2:

Phys: SARA, ALAN

(561) 745-1233

1

City:

State:

Zip:

Page:8

Acc# 005261164 Chart#

First reported on:

Coll. Date: 11/20/24 Coll. Time: 00:00 AM 11/20/24 14:37 Recv. Date: 11/20/24 Recv. Time:07:31 AM Final report date: Print Date: 11/20/24 Print Time: 15:39

11/20/24

Report Status: FINAL

**Test Name** 

Results

Reference Range

Units

\*1) Unless otherwise noted, Tests Performed at : LABCORP, 5610 WEST LA SALLE STREET, TAMPA, FL 33607

CAP